HIV ART in Transgender Individuals
Addressing ART Safety and Tolerability in Transgender Individuals

Released: December 07, 2022

Expiration: December 06, 2023

Jill Blumenthal
Jill Blumenthal, MD, MAS
Jennifer Cocohoba
Jennifer Cocohoba, PharmD, AAHIVP

Activity

Progress
1
Course Completed

In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:

  • Strategies on how to approach different ARV-related toxicities
  • Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
  • Clinically relevant drug–drug interactions related to HIV and gender-affirming care
  • Methods to reduce barriers to ART adherence